Tolerance and Psychedelics

Spend any time reading the pharmacology literature on classic psychedelics and one finding keeps surfacing: repeat exposure within days produces a rapid, near-complete loss of effect. It's one of the more striking features of this drug class, and it raises genuinely interesting questions about receptor biology. But before I get into the neuroscience , and I do want to get into it, because it's fascinating , the legal position in Australia needs to be front and centre.

Psilocybin and psilocin are Schedule 9 prohibited substances under the Therapeutic Goods Administration's Poisons Standard (the SUSMP). Possessing, using, or supplying them outside a specific, narrow approval pathway is a criminal offence in every Australian state and territory. The only lawful pathway for clinical use is via a TGA Authorised Prescriber , a specialist approved to prescribe psilocybin as a Schedule 8 controlled drug for a specific patient, under a framework that has existed since 1 July 2023. Outside that AP pathway, and outside the Special Access Scheme, there is no legal avenue. That's the baseline. Everything below describes published research and pharmacological mechanism; not a guide to use, not a protocol, not a recommendation.

What "tolerance" actually means in pharmacology

Tolerance is a reduction in response to a drug following repeated exposure. It's a common pharmacological phenomenon and it takes different forms depending on the mechanism involved. For most substances, tolerance develops gradually over weeks or months of regular use. For classic psychedelics, psilocybin, LSD, mescaline, DMT, the pattern is unusual: a very rapid onset, and an equally rapid reversal.

The term used in the literature for this within-class effect is cross-tolerance. Research has consistently documented that the major classic psychedelics share it. A person who has recently been exposed to LSD shows markedly reduced response to psilocybin, and vice versa. This is not incidental. It reflects a shared mechanism at the receptor level; specifically, the 5-HT2A serotonin receptor. Understanding why that receptor behaves this way is where the pharmacology gets interesting.

Worth noting: tolerance to psychedelics is a distinct phenomenon from physical dependence. The research does not indicate that classic psychedelics produce the kind of physical dependence associated with opioids or alcohol. The two concepts, tolerance and dependence, are sometimes conflated in public discussion, and it's worth keeping them separate.

The 5-HT2A receptor and the mechanism behind rapid tolerance

The psychedelic effects of compounds like psilocin (the active metabolite of psilocybin after metabolism) are primarily mediated by agonism at the 5-HT2A serotonin receptor; a G protein-coupled receptor found in high density in the cortex, particularly in layer V pyramidal neurons. When these receptors are repeatedly activated over a short period, the cell responds by downregulating receptor density at the surface. This is called receptor internalisation or downregulation, and it's essentially the cell's way of reducing its sensitivity to an overstimulating signal.

A 2021 review published in Pharmacology & Therapeutics (Glatfelter et al.) documented that 5-HT2A receptor downregulation following repeated agonist exposure is rapid and robust, occurring within 24–48 hours and recovering over a similar timeframe. The receptor internalisation is mediated in part by beta-arrestin signalling and is well-characterised in animal models. Human neuroimaging studies, including work using PET to measure receptor occupancy, have provided consistent corroborating evidence, though the human dataset remains smaller.

This mechanism also explains the cross-tolerance effect. Because LSD, psilocin, and mescaline all act primarily via 5-HT2A agonism, downregulation of that receptor from exposure to any one of them reduces the available receptor pool for the others. The receptor doesn't distinguish between the ligands; it only registers the agonist signal, and downregulates in response to it.

The pharmacokinetics of individual compounds affect how quickly tolerance onset and offset occur. LSD's much longer half-life compared to psilocin (roughly 8–10 hours versus 2–3 hours) means its receptor-level effects persist longer, which appears to produce a somewhat more prolonged tolerance window in some studies. But the underlying mechanism is shared.

Tachyphylaxis: the very rapid version

A related term worth knowing is tachyphylaxis, tolerance that develops acutely, sometimes within a single session of repeated dosing. Early research on LSD noted this, and it's been documented in animal models with psilocin. Whether tachyphylaxis is clinically significant in a standard single-exposure context (as opposed to repeated dosing within hours) is less clear, and I'd be cautious about reading too much into some of the older animal literature that used exposure schedules unlikely to map onto anything a human would encounter. The short version is: the receptor-level mechanism is real; the precise kinetics in humans are still being characterised.

What the research community reports about tolerance intervals

I want to be precise here about framing. Published research papers, and some ethnographic and survey literature, have reported what study participants describe as a noticeable reduction in effect from repeat exposures within roughly two to four days, with return toward baseline sensitivity after approximately one to two weeks. These are reported observations from research contexts and self-report surveys, not instructions. Citing them here is for pharmacological education only, and they come with the reminder that any use of psilocybin outside the Authorised Prescriber framework in Australia is illegal and carries serious criminal consequences.

The Australian Drug Foundation has published harm-reduction information noting the rapid tolerance pattern of classic psychedelics, alongside clear statements about their prohibited status in Australia. That's a useful model for how to hold both things at once: pharmacological description and legal reality, neither one obscuring the other.

Cross-tolerance and other serotonergic compounds

There's a genuinely interesting question in the literature about whether 5-HT2A downregulation from psychedelic exposure produces any cross-tolerance with non-psychedelic serotonergic drugs, and vice versa. The evidence here is more complicated. SSRIs (selective serotonin reuptake inhibitors), which chronically elevate synaptic serotonin, have been reported in multiple studies to attenuate psychedelic effects, though the mechanism appears to involve both receptor downregulation and competition at the receptor site. This is an area of active research and the findings are not uniform across studies; I'll admit I find this corner of the literature genuinely messy, in the best way. It suggests the 5-HT2A receptor's regulatory biology is considerably more complex than a simple on/off switch.

None of this, for the avoidance of doubt, constitutes advice about drug combinations. Any interaction with prescription medications is a matter for a licensed health practitioner.

Why this matters for clinical research design

For researchers and clinicians working within the Authorised Prescriber framework, the rapid tolerance and recovery pattern is a genuine practical consideration in study design. Spacing of sessions in clinical trials, and I'm thinking here of the published protocols from the Johns Hopkins Center for Psychedelic and Consciousness Research, among others, has generally reflected awareness of this pharmacology, with sessions typically separated by weeks rather than days. Whether the spacing is driven primarily by tolerance considerations, psychological integration windows, or both, varies by trial design. But the receptor biology provides at least part of the rationale.

I spent an afternoon recently going back through some of the older tolerance literature; Isbell et al. from the 1950s and 60s, which I'd first encountered as a pharmacology undergrad and somehow never fully appreciated for how methodologically interesting it is. Playing a bit of piano that evening while the papers were still sitting in my head, I kept thinking about how much of what we're only now studying formally was sitting in that old data, waiting. Anyway.

The legal framework, again, because it bears repeating

Psilocybin is a Schedule 9 prohibited substance in Australia. Possession, use, or supply outside a TGA-authorised clinical pathway is a criminal offence. The Authorised Prescriber scheme allows specialist-approved practitioners to prescribe Schedule 8 psilocybin for specific patients, this is not a general prescription pathway, and it does not decriminalise personal use. The Special Access Scheme provides a separate but also tightly regulated avenue for unapproved therapeutic goods. For anyone seeking information about these clinical pathways, the TGA's published guidance at tga.gov.au is the authoritative source.

Understanding the pharmacology of tolerance is not a reason to seek out these substances. It's a reason to understand why the clinical research community takes the scheduling of sessions seriously, and why receptor biology is central to how this science is being done.

Sources

• Psilocybin and MDMA Authorised Prescriber information; Therapeutic Goods Administration (TGA)
• LSD drug facts (including tolerance and legal status), Australian Drug Foundation (ADF)
• Glatfelter et al. (2021), Pharmacology & Therapeutics, 5-HT2A receptor regulation by psychedelics; NCBI/PubMed
• Nichols DE (2016), Pharmacological Reviews, Psychedelics, NCBI PMC

, Daniel Okoro, Psychedelic science & law writer